2026
conference-abstract
OpenAlex
Henry John Leonard, Dan Rocca, Philipp Tobias Meyer, Ina Rohleff et autres
Abstract Advances in in vivo-expressed biologics are redefining how advanced modality therapeutics can be manufactured, delivered, and rapidly iterated for oncology and immune-modulating applications. Building on our existing mRNA-LNP platform for therapeutic antibody expression, we now extend this capability to mRNA-encoded chimeric …
gb, de, nl
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Molly Chilton, Henry John Leonard, Elsenoor J. Klaver, Olivier Reelfs et autres
Abstract RNA-based cancer vaccines provide exceptional flexibility for encoding tumour-associated antigens (TAAs) or patient-specific neoantigens and recent clinical data show promising efficacy over traditional approaches, yet comparative functional data across RNA formats remain limited. We developed an integrated evaluation workflow to benchmark …
gb
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Lorena Sueiro-Ballesteros, Henry John Leonard, Dan Rocca, Lauren P. Schewitz‐Bowers et autres
Abstract Cellular homeostasis is maintained through a tightly regulated interplay of metabolic activity, cell cycle progression, programmed cell death, and genomic integrity. Perturbation of these pathways is a hallmark of oncogenesis. Analysis of these processes not only elucidates mechanisms of disease but …
gb
(code pays fourni par la source)
2025
conference-abstract
OpenAlex
Eva J. Oswald, Philipp Tobias Meyer, Loreen Weichert, Roxana Simona Redis et autres
Treatment options for HER2 positive cancer types have advanced significantly over recent years, focusing on targeted therapies that inhibit HER2 signaling and more recently using HER2 as the anchor-signal to bring tumor killing moieties or effector immune cells near the cancer cell. …
de, gb
(code pays fourni par la source)
2024
conference-abstract
OpenAlex
Elsenoor J. Klaver, Henry John Leonard, Elizabeth Lieverse, Stephan Brand et autres
Abstract Many cancers remain resistant to conventional therapies, consequently there has been an exponential rise in the number of therapeutics harnessing the power of the immune system in an oncology setting, with several remarkable examples of success. High frequencies of infiltrating tumor-specific …
gb
(code pays fourni par la source)
2024
conference-abstract
OpenAlex
Roxana Simona Redis, Dan Rocca, Rachel Pooley, Matthew D. Benson et autres
Abstract The manufacturing of therapeutic antibodies requires expensive production, often challenging purification, lengthy stability optimization and complex protein characterization that despite continual improvement, keeps the cost of treatment in the clinic high. Alternatively, leveraging gene-based approaches such as mRNA to express therapeutics …
nl, gb, de
(code pays fourni par la source)
2024
conference-abstract
OpenAlex
Karina Di Gregoli, Henry John Leonard, Dan Rocca, Sabrina de Munnik et autres
Abstract Chimeric Antigen Receptor-Natural Killer (CAR-NK) cells are rapidly emerging as a promising cellular therapeutic overcoming the potential life-threatening adverse events that may result from CAR-T therapy, including cytokine release syndrome (CRS), neurotoxicity and graft-versus-host disease (GVHD). Due to their intrinsic characteristics, …
gb, nl
(code pays fourni par la source)
Accès ouvert
2023
conference-abstract
OpenAlex
Elsenoor J. Klaver, Paulina Goral, Tetiana Herheliuk, Lauren Kelsey et autres
Background Chronic stimulation of CD8 T cells, either as a result of chronic infection or exposure to antigens within the tumor microenvironment, can lead to a state of exhaustion whereby T cells no longer elicit a productive effector response. Re-mobilization of exhausted …
gb
(code pays fourni par la source)
2023
conference-abstract
OpenAlex
Lauren Kelsey, Karin Latta, Joey Kolb, Bincy John et autres
Abstract Chimeric Antigen Receptor (CAR)-T cell therapy has achieved great success in treating a variety of liquid tumors, in particular CD19+ lymphomas. CAR technology is advancing rapidly, with notable improvements in efficacy, safety and complexity as human ingenuity seeks solid tumor applicability. …
gb, us, de
(code pays fourni par la source)
2023
conference-abstract
OpenAlex
Marie Carkill, Kaitlin F. Mitchell, Lauren Kelsey, Jezrom Self-Fordham et autres
Abstract The cancer treatment landscape has transformed following the clinical success of early immune checkpoint inhibitors (ICI) which demonstrate the remarkable power of harnessing the immune system to treat a variety of metastatic cancers. Despite the success of Pembrolizumab, Nivolumab and Atezolizumab, …
gb
(code pays fourni par la source)
2023
conference-abstract
OpenAlex
Rebecca Roberts, Henry John Leonard, Ilona Aylott, Douglas Best et autres
Abstract There has been dramatic progress in the understanding of fundamental causes of cancer, giving rise to novel treatments which harness the power of the immune system to combat cancer progression. Despite this, no two cancers have the same pathogenesis and there …
gb
(code pays fourni par la source)
2023
conference-abstract
OpenAlex
Karina Di Gregoli, Ravindra Mode, Kaitlin F. Mitchell, David Cobeta-Lopez et autres
Abstract Although Chimeric Antigen Receptor (CAR)-T cell therapy has proven to be successful in treating multiple hematological malignancies, their use is limited due to the potential life-threatening adverse events, including cytokine release syndrome (CRS), neurotoxicity and graft-versus-host disease (GVHD). CAR natural killer …
gb, nl
(code pays fourni par la source)